The Big Business Behind Weight Loss Drugs

When Lionel Messi and fellow stars of the FIFA World Cup enter "the zone," what's happening in their brains? Today, neuroscientist Dr. Rui Costa tells Sanjay how you can think like a top athlete and find your own "flow state." This episode was produced by Sofía Sanchez. Medical w ...  Show more

We all know we should brush and floss our teeth. But the reason goes beyond a sparkling smile and keeping bad breath at bay. The mouth is a critical and often overlooked organ when it comes to improving overall health. Dr. Sanjay Gupta sits down with Dr. Kami Hoss, author of “If ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more

$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big- ...  Show more

A new group of drugs for type 2 diabetes and obesity have shown to be more effective for weight loss than any previous medications. Some medications like Ozempic and Wegovy have surged in popularity thanks in part to celebrity use. But who should be taking them? And are they safe ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more